Use of sodium ipodate in management of hyperthyroidism in subacute thyroiditis.

Article Details

Citation
Copy to clipboard

Chopra IJ, van Herle AJ, Korenman SG, Viosca S, Younai S

Use of sodium ipodate in management of hyperthyroidism in subacute thyroiditis.

J Clin Endocrinol Metab. 1995 Jul;80(7):2178-80. doi: 10.1210/jcem.80.7.7608275.

PubMed ID
7608275 [ View in PubMed
]
Abstract

Five hyperthyroid patients (two men and three women) with typical features of subacute thyroiditis were treated with sodium ipodate (Oragrafin; 0.5 g, orally daily or every other day) for 15-60 days; the treatment was stopped when both serum T4 and T3 levels were normal. All patients studied demonstrated a prompt normalization of serum T3, improvement in clinical symptoms of hyperthyroidism, and/or weight gain. We observed no side-effects of treatment with sodium ipodate. Our data suggest that sodium ipodate is a safe and effective agent for management of hyperthyroidism in subacute thyroiditis.

DrugBank Data that Cites this Article

Drugs
Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
Iopodic acidThyroxine 5-deiodinaseProteinHumans
Yes
Antagonist
Details